Clinical Trial Detail

NCT ID NCT03150056
Title Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors GlaxoSmithKline
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Molibresib

Enzalutamide + Molibresib

Prednisone

Age Groups: adult senior

No variant requirements are available.